Idogen’s Nomination Committee proposes re-election of Board of Directors

Report this content


Ahead of the Idogen AB (publ) Annual General Meeting on May 4, 2022, the Nomination Committee has presented its proposal regarding the election of and payment of fees to the Board of Directors and auditor. The Nomination Committee proposes the re-election of the entire Board with Agneta Edberg, Leif Salford, Christina Herder, Sharon Longhurst and Lennart Svensson.  Agneta Edberg is proposed for re-election as Chairman of the Board.


The Nomination Committee ahead of the Annual General Meeting comprised Tobias Ekman (Chairman), Per Eliasson and Leif G. Salford. Chairman of the Board Agneta Edberg was co-opted into the Nomination Committee.


Ahead of the Annual General Meeting, the Nomination Committee proposes that the Board of Directors comprise five ordinary members, and proposes the re-election of Agneta Edberg, Leif G. Salford, Christina Herder, Sharon Longhurst and Lennart Svensson as regular members.


The Nomination Committee proposes the re-election of Agneta Edberg as Chairman of the Board and that Board fees (plus social security contributions) remain unchanged at SEK 300,000 per year be paid to the Chairman and SEK 150,000 each be paid to the other Board members.


Information on the persons proposed for re-election can be found in the Annual Report and on the company’s website (


Additionally, the Nomination Committee proposes that a licensed audit company without deputy be appointed auditor, and that Deloitte AB be re-elected as auditor. Deloitte AB has announced that authorized public accountant Maria Ekelund will remain as auditor in charge. Fees to the auditor will be paid against approved invoices in accordance with customary norms for charging.


The Annual General Meeting of Idogen AB will be held at 3:00 p.m. on May 4, 2022 at Medicon Village, Scheeletorget 1, Lund, Sweden, in the Collaboraction conference room of the main building, Spark. Publication of the notice to attend the meeting is planned for the week of April 5, 2021.



Lund, November 25, 2021

Idogen AB (publ)


For further information, please contact:

Anders Karlsson, CEO, Idogen AB

Tel: +46 (0) 709 18 00 10



Certified Adviser:
Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm
Tel: +46 (0)8 463 80 00


The information was submitted for publication, through the agency of the contact persons set out above, on November 25, 2021 at 11:15 CET.


Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third program, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via




Documents & Links